A Bayesian Optimal Design Advancing The Precision Medicine Approach

By Dr. Pantelis Vlachos, Vice President, Customer Success

There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity), and within an individual (intra‐patient heterogeneity). [1] Traditional designs are challenged by heterogeneity and that has led to the advent of targeted therapies that enable precision medicine. Precision medicine allows physicians to identify individual patient characteristics or tumor types that might be most susceptible to a given therapy and represents a huge advance in cancer care. With the lessons learned from studies conducted over the years, the field has shifted to methods that allow new subgroup discovery during and after the clinical trial.